Composition for treating one or more estrogen related diseases
US11446351B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 25, 2019 |
| Grant date | Sep 20, 2022 |
| Priority date | — |
| Expiry date | Apr 25, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P5/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to treating one or more estrogen related diseases while preventing or reducing the likelihood of developing estrogen deficiency related side effects, wherein the composition comprises administering a therapeutically effective amount of a Gn RH antagonist to a patient in need of the treatment, and wherein the amount of Gn RH antagonist is sufficient for providing a mean endogenous serum estradiol level of between about 20 pg/ml and 60 pg/ml, preferably between 30 pg/ml and 50 pg/m, in the patient in a treatment period of at least four weeks, without relying on “add-back” therapy. The composition and method are simple, effective and will accordingly both increase patient acceptance and compliance of therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.